ArticleNature medicine2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Open access · bronzeAbstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.Frontiers in immunology · 2022Trial
- Review
- Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients.Renal failure · 2023Article
- Article
- Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine.Cell reports. Medicine · 2022Article
- Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.Frontiers in immunology · 2022Article
- Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.Human vaccines & immunotherapeutics · 2021Review
- The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.Immunotherapy advances · 2021Review
Corrections and comments
- Erratum for
Authors and funding
55 authors at 6 institutions in 3 countries.
Jordan R Barrett *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0746-1945
Sandra Belij-Rammerstorfer *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Christina Dold *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Katie J Ewer *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9827-9836
Pedro M Folegatti *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5330-0240
Ciaran Gilbride *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rachel Halkerston *Public Health England, Salisbury, UK.
Jennifer Hill *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Daniel Jenkin *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Daniel.Jenkin@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0003-3088-310X
Lisa Stockdale *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2576-8783
Marije K Verheul *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Parvinder K AleyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Brian AngusNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3598-7784
Duncan BellamyThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Eleanor BerrieClinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Sagida BibiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Mustapha BittayeThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Miles W CarrollClinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Breeze CavellPublic Health England, Salisbury, UK.
Elizabeth A ClutterbuckOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nick EdwardsThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7030-7839
Amy FlaxmanThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Michelle FuskovaThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2146-4299
Andrew GorringePublic Health England, Salisbury, UK.ORCID http://orcid.org/0000-0003-2193-7954
Bassam HallisPublic Health England, Salisbury, UK.
Simon KerridgeThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Alison M LawrieThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Aline LinderOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Xinxue LiuOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Meera MadhavanThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rebecca MakinsonThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jack MellorsPublic Health England, Salisbury, UK.
Angela MinassianThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7832-9824
Maria MooreOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Yama MujadidiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2342-8531
Emma PlestedOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Ian PoultonThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6603-8461
Maheshi N RamasamyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2119-951X
Hannah RobinsonOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Christine S RollierOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9712-8080
Rinn SongOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-6877-1096
Matthew D SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Richard TarrantClinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Stephen TaylorPublic Health England, Salisbury, UK.ORCID http://orcid.org/0000-0002-9936-8539
Kelly M ThomasPublic Health England, Salisbury, UK.ORCID http://orcid.org/0000-0002-0348-654X
Merryn VoyseyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Marion E E WatsonThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-8570-2113
Daniel WrightThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8114-1838
Alexander D DouglasThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5410-7562
Catherine M Green *Clinical BioManufacturing Facility, The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Adrian V S Hill *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0900-9629
Teresa Lambe *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7711-897X
Sarah Gilbert *The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6823-9750
Andrew J Pollard *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Andrew.Pollard@paediatrics.ox.ac.uk.ORCID http://orcid.org/0000-0001-7361-719X
Oxford COVID Vaccine Trial Group
University of Oxford · GBPublic Health England · GBLabCorp (United States) · USAcademy of Medical Sciences · GBCentre for Human Genetics · GBOxford University Hospitals NHS Trust · GB
Funding
Medical Research Council MC_PC_19055Wellcome Trust 109965/Z/15/Z
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.